<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2565-005X</journal-id>
<journal-title><![CDATA[Gaceta mexicana de oncología]]></journal-title>
<abbrev-journal-title><![CDATA[Gac. mex. oncol.]]></abbrev-journal-title>
<issn>2565-005X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Oncología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2565-005X2023000200074</article-id>
<article-id pub-id-type="doi">10.24875/j.gamo.23000107</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación económica de denosumab en pacientes con tumores sólidos con metástasis óseas en el IMSS]]></article-title>
<article-title xml:lang="en"><![CDATA[Economic evaluation of denosumab in patients with solid tumors with bone metastasis at the IMSS]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carlos-Rivera]]></surname>
<given-names><![CDATA[Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guzmán-Caniupan]]></surname>
<given-names><![CDATA[Jorge A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Garduño]]></surname>
<given-names><![CDATA[Adolfo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alva-Esqueda]]></surname>
<given-names><![CDATA[Mónica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aubry-de Maraumont]]></surname>
<given-names><![CDATA[Thérèse]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Camacho-Cordero]]></surname>
<given-names><![CDATA[Luis M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,AHS Health Consulting Departamento de Farmacoeconomía ]]></institution>
<addr-line><![CDATA[Huixquilucan Edo]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,AHS Health Consulting Departamento de Acceso ]]></institution>
<addr-line><![CDATA[Huixquilucan Edo]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,AHS Health Consulting Área Médica ]]></institution>
<addr-line><![CDATA[Huixquilucan Edo]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Amgen México Departamento de Farmacoeconomía ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Amgen México Departamento de Economía de la Salud ]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<volume>22</volume>
<numero>2</numero>
<fpage>74</fpage>
<lpage>83</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2565-005X2023000200074&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2565-005X2023000200074&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2565-005X2023000200074&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Evaluar económicamente el denosumab en comparación con un escenario mixto de ácido zoledrónico o no tratamiento si existe contraindicación a dicho agente por enfermedad renal grave (Mix AZ/No Trt) en pacientes con tumores sólidos (TS) con metástasis ósea.  Método: Análisis de costo-efectividad basado en un modelo Markov, con horizonte temporal de por vida y bajo perspectiva del Instituto Mexicano del Seguro Social. Se evaluaron las frecuencias de eventos relacionados con esqueleto (ERE) y los costos asociados con adquisición de medicamentos, infusión de AZ, manejo de rutina, atención de ERE y tratamiento de eventos adversos serios.  Resultados: En el caso base, denosumab resultó dominante sobre Mix AZ/No Trt, con ahorro promedio de $2,494 pesos y 0.781 ERE evitados por paciente. Si AZ se administra cada 12 semanas, denosumab no sería dominante, pero sí costo-efectivo. El denosumab fue dominante o costo-efectivo en 74.7% de las simulaciones.  Conclusiones: En pacientes con TS con metástasis ósea, denosumab representa una intervención dominante o al menos costo-efectiva frente al Mix AZ/No Trt.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To evaluate denosumab economically compared with a mixed scenario of zoledronic acid or no treatment if there is contraindication to such agent due to severe kidney impairment (Mix ZA/No Trt) in patients with solid tumors (ST) with bone metastasis.  Method: It is a cost-effectiveness analysis based on a Markov model with a lifetime horizon, under the IMSS perspective. We evaluated the frequencies of skeletal-related events (SREs) as well as the costs associated to drug acquisition, intravenous infusion of ZA, routine patient management, medical attention of SREs, and treatment of serious adverse events.  Results: In the base-case, denosumab resulted dominant over Mix ZA/No Trt, with mean savings of $2,494 Mexican pesos and 0.781 SREs avoided per patient. If ZA is given every 12 weeks, denosumab would not be dominant, but cost-effective. Denosumab was either dominant or cost-effective in 74.7% of the simulations.  Conclusions: In patients with ST with bone metastasis, denosumab represents a dominant or at least a cost-effective intervention in comparison with Mix ZA/No Trt.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Evaluación económica]]></kwd>
<kwd lng="es"><![CDATA[Costo-efectividad]]></kwd>
<kwd lng="es"><![CDATA[Denosumab]]></kwd>
<kwd lng="es"><![CDATA[Ácido zoledrónico]]></kwd>
<kwd lng="es"><![CDATA[Eventos relacionados con el esqueleto]]></kwd>
<kwd lng="es"><![CDATA[Tumores sólidos]]></kwd>
<kwd lng="en"><![CDATA[Economic evaluation]]></kwd>
<kwd lng="en"><![CDATA[Cost-effectiveness]]></kwd>
<kwd lng="en"><![CDATA[Denosumab]]></kwd>
<kwd lng="en"><![CDATA[Zoledronic acid]]></kwd>
<kwd lng="en"><![CDATA[Skeletal-related events]]></kwd>
<kwd lng="en"><![CDATA[Solid tumors]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Wade]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Reich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pirolli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Liede]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lyman]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of bone metastases in patients with solid tumors:analysis of oncology electronic medical records in the United States]]></article-title>
<source><![CDATA[BMC Cancer]]></source>
<year>2018</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>44</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Body]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Acklin]]></surname>
<given-names><![CDATA[YP]]></given-names>
</name>
<name>
<surname><![CDATA[Gunther]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathologic fracture and healthcare resource utilisation:A retrospective study in eight European countries]]></article-title>
<source><![CDATA[J Bone Oncol]]></source>
<year>2016</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>185-93</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Body]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sleeboom]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health resource utilization associated with skeletal-related events:results from a retrospective European study]]></article-title>
<source><![CDATA[Eur J Health Econ]]></source>
<year>2016</year>
<volume>17</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>711-21</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matza]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Van Brunt]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health state utilities for skeletal-related events secondary to bone metastases]]></article-title>
<source><![CDATA[Eur J Health Econ]]></source>
<year>2014</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-18</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ivanescu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Phung]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer:data from PREVAIL and AFFIRM trials]]></article-title>
<source><![CDATA[Prostate Cncer Prostatic Dis]]></source>
<year>2017</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>110-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barlev]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Ivanov]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Setty]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer]]></article-title>
<source><![CDATA[J Manag Care Pharm]]></source>
<year>2010</year>
<volume>16</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>693-702</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Body]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gunther]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost of skeletal complications from bone metastases in six European countries]]></article-title>
<source><![CDATA[J Med Econ]]></source>
<year>2016</year>
<volume>19</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>611-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhowmik]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Intorcia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2019</year>
<volume>35</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>513-23</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Clézardin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis]]></article-title>
<source><![CDATA[Am J Clin Oncol]]></source>
<year>2002</year>
<volume>25</volume>
<numero>(6 Suppl 1)</numero>
<issue>(6 Suppl 1)</issue>
<page-range>S3-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ávila Monteverde]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bañuelos García]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Capdeville-García]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guías de manejo de salud ósea en cáncer de mama]]></article-title>
<source><![CDATA[GAMO]]></source>
<year>2007</year>
<volume>6</volume>
<numero>(2 Suppl)</numero>
<issue>(2 Suppl)</issue>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yong]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Onukwugha]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mullins]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer]]></article-title>
<source><![CDATA[Curr Opin Oncol]]></source>
<year>2014</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>274-83</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gül]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sendur]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Aksoy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sever]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Altundag]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comprehensive review of denosumab for bone metastasis in patients with solid tumors]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2016</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>133-45</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yee]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Raje]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Denosumab for the treatment of bone disease in solid tumors and multiple myeloma]]></article-title>
<source><![CDATA[Future Oncol]]></source>
<year>2018</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>195-203</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<source><![CDATA[Guía para la Conducción de Estudios de Evaluación Económica para la Actualización del Cuadro Básico de Insumos del Sector Salud en México]]></source>
<year>2017</year>
<publisher-name><![CDATA[Dirección General Adjunta de Priorización Comisión Interinstitucional del Cuadro Básico y Catálogo de Insumos del Sector Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<collab>International Agency for Research on Cancer</collab>
<source><![CDATA[Global Cancer Observatory:Cancer Today]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cayetano-Alcaraz]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Rivera]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Sotomayor-de-Zavaleta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características de los casos incidentes de cáncer de próstata en los últimos 5 años en un hospital de tercer nivel en México]]></article-title>
<source><![CDATA[Rev Mex Urol]]></source>
<year>2016</year>
<volume>76</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>76-80</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maffuz-Aziz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Labastida-Almendaro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Espejo-Fonseca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Cuevas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características clinicopatológicas del cáncer de mama en una población de mujeres en México]]></article-title>
<source><![CDATA[Cir Cir]]></source>
<year>2017</year>
<volume>85</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>201-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arrieta]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Tirado]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Báez-Saldaña]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Peña-Curiel]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Soca-Chafre]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Macedo-Perez]]></surname>
<given-names><![CDATA[EO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the &#8220;Hispanic paradox&#8221;]]></article-title>
<source><![CDATA[Lung Cancer]]></source>
<year>2015</year>
<volume>90</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>161-6</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burbano Luna]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Manrique]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Chávez García]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiología del cáncer colorrectal en menores de 50 años en el Hospital Juárez de México]]></article-title>
<source><![CDATA[Endoscopia]]></source>
<year>2016</year>
<volume>28</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>160-5</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medrano-Guzmán]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Valencia-Mercado]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Luna-Castillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García-Ríos]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[González-Rodríguez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores pronóstico de sobrevida en adenocarcinoma gástrico avanzado resecable]]></article-title>
<source><![CDATA[Cirugía y Cirujanos]]></source>
<year>2016</year>
<volume>84</volume>
<page-range>469-76</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Granados-García]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Piña-Sánchez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Reynoso-Noveron]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medical Cost to Treat Cervical Cancer Patients at a Social Security Third Level Oncology Hospital in Mexico City]]></article-title>
<source><![CDATA[Asian Pac J Cancer Prev]]></source>
<year>2019</year>
<volume>20</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1547-54</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lino-Silva]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez-Rodríguez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar-Romero]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Melanoma in Mexico:Clinicopathologic Features in a Population with Predominance of Acral Lentiginous Subtype]]></article-title>
<source><![CDATA[Ann Surg Oncol]]></source>
<year>2016</year>
<volume>23</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>4189-94</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acosta-Jiménez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jerónimo-Guerrero]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Macías-Clavijo]]></surname>
<given-names><![CDATA[M de los A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoma de células renales:factores patológicos pronósticos, estadificación y clasificación histopatológica]]></article-title>
<source><![CDATA[Rev Med Inst Mex Seguro Soc]]></source>
<year>2015</year>
<volume>53</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>454-65</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arellano]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Wade]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States]]></article-title>
<source><![CDATA[Cancer Med]]></source>
<year>2015</year>
<volume>4</volume>
<numero>(5)</numero>
<issue>(5)</issue>
<page-range>713-20</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<collab>Diccionario de Especialidades Farmacéuticas PLM Thompson®. México</collab>
<source><![CDATA[ZOMETA®Solución Inyectable]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stopeck]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rader]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of denosumab vs. zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States]]></article-title>
<source><![CDATA[J Med Econ]]></source>
<year>2012</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>712-23</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cristino]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Finek]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jandova]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic]]></article-title>
<source><![CDATA[J Med Econ]]></source>
<year>2017</year>
<volume>20</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>799-812</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stopeck]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brufsky]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States]]></article-title>
<source><![CDATA[J Med Econ]]></source>
<year>2020</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>37-47</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fizazi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Carducci]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer:a randomised, double-blind study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2011</year>
<volume>377</volume>
<numero>9768</numero>
<issue>9768</issue>
<page-range>813-82</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stopeck]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Lipton]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Body]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer:a randomized, double-blind study]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2010</year>
<volume>28</volume>
<numero>35</numero>
<issue>35</issue>
<page-range>5132-9</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vadhan-Raj]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hirsh]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer:an analysis of data from patients with solid tumors]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2014</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>679-87</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lipton]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fizazi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Stopeck]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2016</year>
<volume>53</volume>
<page-range>75-83</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="">
<collab>Compranet</collab>
<collab>Secretaria de Hacienda y Crédito Público</collab>
<source><![CDATA[Claves Adjudicadas en la Compra Consolidada de Medicamentos y Material de Curación]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="">
<collab>Portal IMSS Compró</collab>
<source><![CDATA[Instituto Mexicano del Seguro Social]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="">
<collab>Instituto Mexicano del Seguro Social. Listado de costos unitarios por nivel de atención médica para 2018 desglosados en operativo (sustantivo más apoyo) y corporativo.</collab>
<source><![CDATA[Listado de costos unitarios por nivel de atención médica para 2018 desglosados en operativo (sustantivo más apoyo) y corporativo]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Narazaki]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[de Alverga Neto]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Baptista]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Caiero]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[de Camargo]]></surname>
<given-names><![CDATA[OP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic factors in pathologic fractures secondary to metastatic tumors]]></article-title>
<source><![CDATA[Clinics (Sao Paulo)]]></source>
<year>2006</year>
<volume>61</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>313-20</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trujillo-González]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nieto-Lucio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mendoza-Breton]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidencia de fracturas patológicas por metástasis en el fémur proximal en un hospital de concentración]]></article-title>
<source><![CDATA[Acta Ortopédica Mexicana]]></source>
<year>2016</year>
<volume>30</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>176-80</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="">
<collab>Grupos Relacionados con el Diagnóstico</collab>
<source><![CDATA[Costo Unitario_2018. Nivel Operativo-Sustantivo]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dimai]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Redlich]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Peretz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Borgström]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Siebert]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Mahlich]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic burden of osteoporotic fractures in Austria]]></article-title>
<source><![CDATA[Health Econ Rev]]></source>
<year>2012</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>12</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Himelstein]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Khatcheressian]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of Longer-Interval vs. Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases:A Randomized Clinical Trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2017</year>
<volume>317</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>48-58</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
